3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Nivolumab
3
ulixertinib
2
dabrafenib
2
binimetinib
2
Surveys and Questionnaires
2
Sunitinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cetuximab
2
CTLA-4 Antigen
2
Biopsy
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
selpercatinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
gallium Ga 68 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.